Abstract:ADVERTISEMENT RETURN TO ISSUEPREVAddition/CorrectionNEXTORIGINAL ARTICLEThis notice is a correctionCorrection to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide DonorWenwen Duan, Jin Li, Elizabeth S. Inks, C. James Chou, Yuping Jia, Xiaojing Chu, Xiaoyang Li, Wenfang Xu*, and Yingjie Zhang*Cite this: J. Med. Chem. 2015, 58, 15, 6319Publication Date (Web):July 30, 2015Publication History Published online30 July 2015Published inissue 13 August 2015https://doi.org/10.1021/acs.jmedchem.5b01075Copyright © 2015 American Chemical SocietyRIGHTS & PERMISSIONSArticle Views888Altmetric-Citations3LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InReddit PDF (110 KB) Get e-Alerts Get e-Alerts

Correction to "Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73"

Discovery of Novel Non-Nucleoside Inhibitors Interacting with Dizinc Ions of CD73

Correction to "Discovery of Novel Acridane-Based Tubulin Polymerization Inhibitors with Anticancer and Potential Immunomodulatory Effects"

Correction: Discovery of novel non-peptidic and non-covalent small-molecule 3CL pro inhibitors as potential candidate for COVID-19 treatment

Correction to "Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors"

Design, synthesis and structure-activity relationship of malonic acid non-nucleoside derivatives as potent CD73 inhibitors

Discovery of Novel 5-(Pyridazin-3-yl)pyrimidine-2,4(1 H,3 H)-dione Derivatives as Potent and Orally Bioavailable Inhibitors Targeting Ecto-5'-nucleotidase

Correction to "Discovery of CMX990: A Potent SARS-CoV-2 3CL Protease Inhibitor Bearing a Novel Warhead"

Correction to Design, Synthesis, and Antitumor Evaluation of Novel Histone Deacetylase Inhibitors Equipped with a Phenylsulfonylfuroxan Module as a Nitric Oxide Donor.

Corrigendum: Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity

Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2

Correction to "Discovery of Selenium-Containing STING Agonists as Orally Available Antitumor Agents"

Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

Discovery of novel non-peptidic and non-covalent small-molecule 3CL pro inhibitors as potential candidate for COVID-19 treatment

Identification of Phelligridin-Based Compounds as Novel Human CD73 Inhibitors

Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease

Discovery and optimization of betulinic acid derivatives as novel potent CD73 inhibitors.

Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators

Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum IV Complexes as Potent Antitumor Agents

Discovery of Novel Nonpeptidic and Noncovalent Small Molecule 3CL pro Inhibitors as anti-SARS-CoV-2 Drug Candidate

Computational study of novel natural inhibitors targeting aminopeptidase N(CD13)